Program
HRS-9231
A development code. Also written as “HRS-9231 Injection”.
In Jiangsu HengRui Medicine's pipeline, Gd Contrast agent
. Its studies are led by Jiangsu HengRui Medicine.
Furthest: phase 3, since Nov 18, 20255 company-led studies, 1 open or running
Who develops it
Each company that leads studies of it, as its sponsor page counts them.
| Company | Studies it leads | Furthest phase | First study | Next primary completion |
|---|---|---|---|---|
| Jiangsu HengRui Medicine | 51 open or running | phase 3since Nov 18, 2025 | Oct 23, 2024 | none ahead |
- Named in Jiangsu HengRui Medicine’s own pipeline as
HRS-9231
, phase 3, as of Jul 31, 2026 (source).
History and what’s ahead
From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.
- Oct 23, 2024First study: phase 1 study in Contrast-Enhanced Magnetic Resonance Imaging DetectionFirst studyNCT06657560 · 41 enrolled · China
- Dec 9, 2024Phase 2 study in For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) LesionsNCT06731829 · 78 planned · China
- Aug 8, 2025Phase 1 study in Healthy VolunteersNCT07123376 · 40 enrolled · China
- Nov 18, 20252 phase 3 studiesPhase 3 reachedNCT07275814, NCT07275723
TargetBeta
A vaccine: it acts on a pathogen, not a human gene.
“Gd Contrast agent”the company's pipeline, read by Claude · source
Studies
All 5 led by companies developing it, newest first. Each opens its study page.
| Study | Phase | Status | Primary completion | Size |
|---|---|---|---|---|
| NCT07275814For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions · China | 3 | Completed | Jun 17, 2026 | 250 |
| NCT07275723For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Abnormal Vascular Lesions in Body Regions Excluding the Central Nervous System (CNS) · China | 3 | Completed | Apr 18, 2026 | 309 |
| NCT07123376Healthy Volunteers · China | 1 | Completed | Oct 6, 2024 | 40 |
| NCT06731829For Contrast-enhanced Magnetic Resonance Imaging (MRI) of Central Nervous System (CNS) Lesions · China | 2 | Not yet recruiting | Apr 2025 | 78 |
| NCT06657560Contrast-Enhanced Magnetic Resonance Imaging Detection · China | 1 | Completed | Jul 3, 2025 | 41 |
How it is read
Names in the registry
- “HRS-9231”, 3 entries
- “HRS-9231 Injection”, 2 entries
Codes read as this program: HRS9231.
Conditions, from the studies’ own filings
First seen by our ledger Nov 13, 2026.
What this can’t show
- Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
- Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
- Primary completion dates are the sponsors’ estimates and often move.
- A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.